Literature DB >> 19637874

Design and synthesis of novel C14-hydroxyl substituted triptolide derivatives as potential selective antitumor agents.

Zheng Li1, Zhao-Li Zhou, Ze-Hong Miao, Li-Ping Lin, Hui-Jin Feng, Lin-Jiang Tong, Jian Ding, Yuan-Chao Li.   

Abstract

It has long been considered that the free beta hydroxyl group at C14 of triptolide (1) is essential to its potent anticancer activity. In this study, we synthesized novel derivatives of 1 with a hydroxyl group substituted by epoxy groups (4-8) or a five-membered ring (11-13). Compounds (4-8) showed significant in vitro anticancer activity although less potent than 1. Although with an alpha oxygen configuration at the C14 position, (14S)-14,21-epoxytriptolide (4) exhibited the highest potency among all these derivatives, clearly challenging the traditional viewpoint on the necessity of C14beta-hydroxyl group of compound 1. Further studies revealed that while displaying broad spectrum in vitro anticancer activity, compound 4 demonstrated prominent selective in vivo anticancer activity, particularly against human ovarian SK-OV-3 and prostate PC-3 cancers with obviously lower toxicity than 1. Noticeably, compound 4 was also highly effective against multidrug resistant cancer cells. Therefore, our study gives new insights into the structure-activity relationship of 1 and also produces a promising anticancer drug candidate with unique anticancer activities.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19637874     DOI: 10.1021/jm900342g

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  10 in total

1.  XPB, a subunit of TFIIH, is a target of the natural product triptolide.

Authors:  Denis V Titov; Benjamin Gilman; Qing-Li He; Shridhar Bhat; Woon-Kai Low; Yongjun Dang; Michael Smeaton; Arnold L Demain; Paul S Miller; Jennifer F Kugel; James A Goodrich; Jun O Liu
Journal:  Nat Chem Biol       Date:  2011-01-30       Impact factor: 15.040

Review 2.  Targeting apoptosis pathway with natural terpenoids: implications for treatment of breast and prostate cancer.

Authors:  Huanjie Yang; Q Ping Dou
Journal:  Curr Drug Targets       Date:  2010-06       Impact factor: 3.465

3.  Increased accumulation of hypoxia-inducible factor-1α with reduced transcriptional activity mediates the antitumor effect of triptolide.

Authors:  Zhao-Li Zhou; Zhi-Guo Luo; Bing Yu; Yi Jiang; Yi Chen; Jian-Ming Feng; Mei Dai; Lin-Jiang Tong; Zheng Li; Yuan-Chao Li; Jian Ding; Ze-Hong Miao
Journal:  Mol Cancer       Date:  2010-10-11       Impact factor: 27.401

4.  Oxymatrine enhanced anti-tumor effects of Bevacizumab against triple-negative breast cancer via abating Wnt/β-Catenin signaling pathway.

Authors:  Wei Xie; Yan Zhang; Shiwei Zhang; Fengxian Wang; Kunchi Zhang; Yanjuan Huang; Zhaoli Zhou; Gang Huang; Jin Wang
Journal:  Am J Cancer Res       Date:  2019-08-01       Impact factor: 6.166

5.  Development of Potential Antitumor Agents from the Scaffolds of Plant-Derived Terpenoid Lactones.

Authors:  Yulin Ren; A Douglas Kinghorn
Journal:  J Med Chem       Date:  2020-12-08       Impact factor: 7.446

6.  Critical Role of Hepatic Cyp450s in the Testis-Specific Toxicity of (5R)-5-Hydroxytriptolide in C57BL/6 Mice.

Authors:  Cunzhi Yu; Yu Li; Mingxia Liu; Man Gao; Chenggang Li; Hong Yan; Chunzhu Li; Lihan Sun; Liying Mo; Chunyong Wu; Xinming Qi; Jin Ren
Journal:  Front Pharmacol       Date:  2017-11-21       Impact factor: 5.810

7.  Triptolide Inhibits the AR Signaling Pathway to Suppress the Proliferation of Enzalutamide Resistant Prostate Cancer Cells.

Authors:  Yangyang Han; Weiwei Huang; Jiakuan Liu; Dandan Liu; Yangyan Cui; Ruimin Huang; Jun Yan; Ming Lei
Journal:  Theranostics       Date:  2017-04-20       Impact factor: 11.556

8.  Natural products triptolide, celastrol, and withaferin A inhibit the chaperone activity of peroxiredoxin I.

Authors:  Qian Zhao; Yu Ding; Zhangshuang Deng; On-Yi Lee; Peng Gao; Pin Chen; Rebecca J Rose; Hong Zhao; Zhehao Zhang; Xin-Pei Tao; Albert J R Heck; Richard Kao; Dan Yang
Journal:  Chem Sci       Date:  2015-05-19       Impact factor: 9.825

9.  Redox-responsive self-assembly PEG nanoparticle enhanced triptolide for efficient antitumor treatment.

Authors:  Yanchun Wang; Xuewei Liu; Xuemei Wang; Wei Zheng; Junping Zhang; Feng Shi; Junbao Liu
Journal:  Sci Rep       Date:  2018-08-28       Impact factor: 4.379

10.  Improved Antitumor Outcomes for Colon Cancer Using Nanomicelles Loaded with the Novel Antitumor Agent LA67.

Authors:  Minhu Cui; Mingji Jin; Mingfeng Han; Yingda Zang; Chuangjun Li; Dongming Zhang; Wei Huang; Zhonggao Gao; Xuezhe Yin
Journal:  Int J Nanomedicine       Date:  2020-05-19
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.